AbbVie received European Commission approval for MAVIRET, an antiviral used to treat acute and chronic Hepatitis C. The approval expands the drug's regulatory reach in Europe and is a positive commercial development for the company. The news is constructive for AbbVie but is unlikely to materially move the broader market.
AbbVie received European Commission approval for MAVIRET, an antiviral used to treat acute and chronic Hepatitis C. The approval expands the drug's regulatory reach in Europe and is a positive commercial development for the company. The news is constructive for AbbVie but is unlikely to materially move the broader market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
